Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 15/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5744384 | 1.00 | KDM1A (0.51) | KDM1AMAOBTACR1KMT2AL3MBTL1 | |
| SCHEMBL5745869 | 1.00 | KDM1A (0.51) | KDM1AMAOBTACR1KMT2AL3MBTL1 | |
| SCHEMBL6311266 | 1.00 | KDM1A (0.51) | KDM1AMAOBTACR1KMT2AL3MBTL1 | |
| SCHEMBL5744393 | 1.00 | KDM1A (0.51) | KDM1AMAOBTACR1KMT2AL3MBTL1 | |
| SCHEMBL12596343 | 0.92 | KDM1A (0.53) | KDM1AMAOBTACR1KMT2AL3MBTL1 | |
| SCHEMBL19988415 | 0.87 | KDM1A (0.47) | KDM1ATACR1CYP2D6 | |
| SCHEMBL6310438 | 0.85 | KDM1A (0.41) | KDM1AMAOBKMT2AL3MBTL1EPHX2 | |
| SCHEMBL6828195 | 0.81 | SMN1; SMN2 (0.53) | TACR1 | |
| SCHEMBL3376268 | 0.79 | ALDH1A1 (0.50) | TACR1 | |
| SCHEMBL22721975 | 0.79 | ALDH1A1 (0.50) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638935-A1 | NK1 ANTAGONIST | Pfizer Products Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004110996-A1 | NK1 ANTAGONIST | PFIZER PRODUCTS INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | KDM1A 1794/4885MAOB 1849/4885TACR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.